Gossamer Bio, Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

GOSS$11.28+6.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Deficit

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(in thousands, except share amounts)

Common stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive income (loss) · Total stockholders' equity (deficit)
Shares · Amount
Balance as of December 31, 2025	233,677,057	$24	$1,321,303	$(1,438,938)	$(5,149)	$(122,760)
Exercise of stock options	211,460	—	220	—	—	220
Stock-based compensation	—	—	6,304	—	—	6,304
Issuance of common stock pursuant to Employee Stock Purchase Plan	807,765	—	292	—	—	292
Net loss	—	—	—	(46,664)	—	(46,664)
Other comprehensive income	—	—	—	—	1,125	1,125
Balance as of March 31, 2026	234,696,282	$24	$1,328,119	$(1,485,602)	$(4,024)	$(161,483)
Stock-based compensation	—	—	2,463	—	—	2,463
Issuance of common stock and warrants in connection with the exchange of the 2027 Notes, net of issuance costs	254,150,441	26	47,775	—	—	47,801
Net income	—	—	—	16,900	—	16,900
Other comprehensive income	—	—	—	—	290	290
Balance as of June 30, 2026	488,846,723	$50	$1,378,357	$(1,468,702)	$(3,734)	$(94,029)

Common stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive income (loss) · Total stockholders' equity (deficit)
Shares · Amount
Balance as of December 31, 2024	226,604,138	$23	$1,296,848	$(1,268,568)	$1,189	$29,492
Exercise of stock options	112,617	—	132	—	—	132
Stock-based compensation	—	—	2,405	—	—	2,405
Issuance of common stock pursuant to Employee Stock Purchase Plan	504,507	—	372	—	—	372
Net loss	—	—	—	(36,638)	—	(36,638)
Other comprehensive loss	—	—	—	—	(2,013)	(2,013)
Balance as of March 31, 2025	227,221,262	$23	$1,299,757	$(1,305,206)	$(824)	$(6,250)
Vesting of restricted stock	—	—	—	—	—	—
Exercise of stock options	101,266	—	94	—	—	94
Stock-based compensation	—	—	2,586	—	—	2,586
Net loss	—	—	—	(38,273)	—	(38,273)
Other comprehensive loss	—	—	—	—	(4,264)	(4,264)
Balance as of June 30, 2025	227,322,528	$23	$1,302,437	$(1,343,479)	$(5,088)	$(46,107)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.